Blood Vessels News and Research

RSS

Schering and Novartis agree on joint commercialization of novel cancer drug

Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.

25 Jan 2005

Heart patients with gastrointestinal complications should use low doses of aspirin combined with drugs that treat stomach ulcers

Physicians are challenged in treating heart patients who may be at high-risk for gastrointestinal bleeding from aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Factors that place patients at high-risk include a history of ulcers or gastrointestinal complications such as bleeding, increased age and congestive heart failure.

20 Jan 2005

Animal study on vascular effects of COX-2 inhibition

In an article by Egan et al, titled, "Cyclooxygenases, Thromboxane, and Atherosclerosis," published in the Jan 17 issue of Circulation: Journal of the American Heart Association researchers examined some of the molecular mechanisms of drugs affecting prostaglandin and thromboxane production.

17 Jan 2005

Research leads to new antiangiogenic drugs

Scientists have uncovered critical information that may lead to an urgently needed method for effective monitoring of antiangiogenic cancer therapies.

17 Jan 2005

Exciting research into the use of aspirin for reducing heart attacks, strokes and dementia

A consortium of researchers led by Monash University will receive more than $3.5 million in Australian Government funding for research into the use of aspirin for reducing heart attacks, strokes and dementia in older Australians.

17 Jan 2005

Avastin available across Europe within the next few weeks

Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer.

16 Jan 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

Reduced progression of atherosclerosis tied to statin drugs lowering fats, protein

Aggressive therapy with statins -- drugs that inhibit cholesterol synthesis -- works better than moderate statin therapy in reducing fats and proteins in the blood that have been linked to atherosclerosis, a new multi-center study concludes. Statins’ effects on both complex compounds appear beneficial in cutting patients’ cardiovascular risks.

6 Jan 2005

Stem cells from umbilical cord blood effectively treated heart attacks

When injected into rats' hearts soon after a heart attack, stem cells taken from human umbilical cord blood (HUCB) greatly reduced the size of heart damage and restored pumping function to near normal. This improvement occurred without the need for drugs to prevent the rats' immune system from rejecting the human cells.

5 Jan 2005

New protein discovered holds promise for use in medicine and nanoscience

Researchers at the Hebrew University of Jerusalem have succeeded in discovering and isolating a new protein from the poplar tree with special structural and qualitative characteristics that could have consequences for development of future nanocapsules for drug delivery to cancer cells.

5 Jan 2005

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration

Results from two concurrent, prospective, double-blind, multi-center clinical trials show that pegaptanib (Macugen), an anti-vascular endothelial growth factor therapy, is an effective treatment for neovascular age-related macular degeneration (AMD), according to a paper in the Dec. 30 issue of the New England Journal of Medicine. Macugen was approved by the Food and Drug Administration on Dec. 17.

30 Dec 2004

Brisk walks substantially improve blood vessel function both before and during the hours after eating a fatty meal

A 90-minute walk lowered triglycerides and improved blood vessel function in a small group of lean and obese men, and the benefits persisted into the following day, even after participants ate a fatty meal, according to a new study in the Dec. 21, 2004 issue of the Journal of the American College of Cardiology.

21 Dec 2004

Timing of radiation and antiangiogenic therapy impacts treatment effectiveness

Agents designed to attack blood vessels that feed a growing tumor are effective against tumor growth in laboratory experiments. However, results of early clinical trials with these inhibitors have not yet exhibited the same success observed in animal models.

20 Dec 2004

Macugen approved for the treatment of neovascular (wet) age-related macular degeneration (AMD)

Eyetech Pharmaceuticals and Pfizer have announced that the U.S. Food and Drug Administration (FDA) approved Macugen (pegaptanib sodium injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.

20 Dec 2004

Model may explain how alcohol stimulates tumor growth

The investigators found that compared to the saline control group, the embryos exposed to ethanol experienced increases in tumor size, tumor blood vessel density, cancer cell infiltration of blood vessels, and VEGF levels.

13 Dec 2004

Study supports the use of the internal mammary artery in coronary artery bypass grafting

Long-term follow up with heart bypass patients treated in Veterans Affairs hospitals shows that 85 percent of left internal mammary artery grafts and 61 percent of vein grafts remain open (patent) after 10 years, and that these grafts are more likely to offer long-term success when they are attached to larger arteries on the heart, according to a new study in the Dec. 7, 2004 issue of the Journal of the American College of Cardiology.

8 Dec 2004

Noninvasive test of blood flow response may reveal early coronary disease

Chest pain patients who have abnormal coronary blood vessel function also have less responsive blood vessels in their fingertips, suggesting that a type of fingertip probe could become a useful screening tool, according to a new study in the Dec. 7, 2004 issue of the Journal of the American College of Cardiology.

8 Dec 2004

Defect in one of nature's oldest proteins may be an underlying cause in human miscarriages

University of Rochester scientists studying a vital protein called Serum Response Factor (SRF) in mice have learned new and unexpected facts about SRF's role in early cardiovascular development, and how a defect in this gene may be an underlying cause in human miscarriages.

8 Dec 2004

New insight into anticoagulation therapies

Anticoagulation therapies, or treatments that reduce the amount of clotting factors in the blood, are quite common and used for a variety of reasons.

6 Dec 2004

New advances in sickle cell disease

Excruciating pain episodes, recurrent pneumonias, strokes, severe infections, chronic hemolytic anemia, and secondary pulmonary hypertension are common complications of sickle cell disease, a life-threatening inherited defect in blood that causes normally disc-shaped red blood cells to take on a sickle shape.

6 Dec 2004

Blood Vessels News and Research

Schering and Novartis agree on joint commercialization of novel cancer drug

Heart patients with gastrointestinal complications should use low doses of aspirin combined with drugs that treat stomach ulcers

Animal study on vascular effects of COX-2 inhibition

Research leads to new antiangiogenic drugs

Exciting research into the use of aspirin for reducing heart attacks, strokes and dementia

Avastin available across Europe within the next few weeks

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Reduced progression of atherosclerosis tied to statin drugs lowering fats, protein

Stem cells from umbilical cord blood effectively treated heart attacks

New protein discovered holds promise for use in medicine and nanoscience

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration

Brisk walks substantially improve blood vessel function both before and during the hours after eating a fatty meal

Timing of radiation and antiangiogenic therapy impacts treatment effectiveness

Macugen approved for the treatment of neovascular (wet) age-related macular degeneration (AMD)

Model may explain how alcohol stimulates tumor growth

Study supports the use of the internal mammary artery in coronary artery bypass grafting

Noninvasive test of blood flow response may reveal early coronary disease

Defect in one of nature's oldest proteins may be an underlying cause in human miscarriages

New insight into anticoagulation therapies

New advances in sickle cell disease

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News